Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Sodium valproate (Episenta®) is recommended as an option for use within NHS Wales for the treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. The continuation of treatment after manic episode could be considered in patients who have responded to sodium valproate (Episenta®) for acute mania. AWMSG is of the opinion that sodium valproate (Episenta®) may be suitable for shared care within NHS Wales. |
|||
|
|||
Medicine details |
|||
| Medicine name | sodium valproate (Episenta®) | ||
| Formulation | 150 mg, 300 mg, 500 mg prolonged-release capsule, 1000 mg prolonged-release granules | ||
| Reference number | 1178 | ||
| Indication | Treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. The continuation of treatment after manic episode could be considered in patients who have responded to sodium valproate for acute mania |
||
| Company | Beacon Pharmaceuticals Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2111 | ||
| NMG meeting date | 03/11/2011 | ||
| AWMSG meeting date | 07/12/2011 | ||
| Ratification by Welsh Government | 09/01/2012 | ||
| Date of issue | 12/01/2012 | ||